SBT-115301 is under clinical development by Sonoma Biotherapeutics and currently in Phase I for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase I drugs for Type 1 Diabetes (Juvenile Diabetes) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SBT-115301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SBT-115301 overview

SBT-115301 is under development for the treatment of type 1 diabetes. The therapeutic candidate is developed based on T effector cells (Teff) debulking protein therapeutic platform.

Sonoma Biotherapeutics overview

Sonoma Biotherapeutics (Sonoma) is a biotechnology company that is involved in the development of adoptive Treg therapy cells for autoimmune and degenerative diseases. It is investing in its pipeline products which include SBT-77-7101, SBT-77-7200 Series, and SBT-11-5301 for the discovery of drugs targeted for the treatment of autoimmune and inflammatory diseases. The company leverages its regulatory T cells (Treg cells) which facilitate engineering and genetic reprogramming to suppress autoimmune diseases and maintain immune homeostasis. Its key funding partners include 8VC, Alexandria Venture Investments, Ally Bridge Group, and Arrowmark Partners, among others. Sonoma is headquartered in South San Francisco, California, United States.

For a complete picture of SBT-115301’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.